Literature DB >> 11046067

Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects.

M P Pender1, P A Csurhes, J M Greer, P D Mowat, R D Henderson, K D Cameron, D M Purdie, P A McCombe, M F Good.   

Abstract

We have previously shown that patients with multiple sclerosis (MS) have increased T cell responses to the immunodominant region (residues 184-209) of myelin proteolipid protein (PLP). The present study investigated whether this reactivity fluctuates over time and correlates with disease activity. We performed monthly limiting dilution assays for 12-16 mo in four healthy subjects and five patients with relapsing-remitting MS to quantify the frequencies of circulating T cells proliferating in response to PLP(41-58), PLP(184-199), PLP(190-209), myelin basic protein (MBP), MBP(82-100), and tetanus toxoid. Disease activity was monitored by clinical assessment and gadolinium-enhanced magnetic resonance imaging of the brain. There were fluctuations in the frequencies of autoreactive T cells in all subjects. Compared with healthy controls, MS patients had significantly more frequent surges of T cells reactive to the 184-209 region of PLP, but infrequent surges of T cell reactivity to MBP(82-100). There was temporal clustering of the surges of T cell reactivity to MBP(82-100) and MBP, suggesting T cell activation by environmental stimuli. Some clinical relapses were preceded by surges of T cell reactivity to PLP(184-209), and in one patient there was significant correlation between the frequency of T cells reactive to PLP(184-199) and the total number of gadolinium-enhancing magnetic resonance imaging lesions. However, other relapses were not associated with surges of T cell reactivity to the Ags tested. T cells reactive to PLP(184-209) may contribute to the development of some of the CNS lesions in MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046067     DOI: 10.4049/jimmunol.165.9.5322

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 2.  Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Authors:  Ai-Lan Nguyen; Melissa Gresle; Tessa Marshall; Helmut Butzkueven; Judith Field
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

3.  Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders.

Authors:  Paolo A Muraro; Klaus-Peter Wandinger; Bibiana Bielekova; Bruno Gran; Adriana Marques; Ursula Utz; Henry F McFarland; Steve Jacobson; Roland Martin
Journal:  Brain       Date:  2003-01       Impact factor: 13.501

Review 4.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

5.  Reactivity of T cells from women with antibodies to the human platelet antigen (HPA)-1a to peptides encompassing the HPA-1 polymorphism.

Authors:  D J Jackson; M F Murphy; P W Soothill; G F Lucas; C J Elson; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

7.  Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein.

Authors:  Trygve Holmøy; Espen Østhagen Kvale; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

8.  Reduction of human anti-tetanus toxoid antibody in hu-PBL-SCID mice by immunodominant peptides of tetanus toxoid.

Authors:  D J Jackson; C J Elson; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

9.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

10.  Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis.

Authors:  Arthur A Vandenbark; Nicole E Culbertson; Richard M Bartholomew; Jianya Huan; Marci Agotsch; Dorian LaTocha; Vijayshree Yadav; Michele Mass; Ruth Whitham; Jesus Lovera; June Milano; Georgia Theofan; Yuan K Chou; Halina Offner; Dennis N Bourdette
Journal:  Immunology       Date:  2007-10-16       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.